Print

September is Dystonia Awareness Month

An estimated 250,000 people in the United States have dystonia, a chronic movement disorder affecting the brain and nervous system. It is the third most common movement disorder after essential tremor and Parkinson disease. Dystonia causes excessive, uncontrollable muscle spasms. The muscle spasms twist the body and limbs into involuntary movements and awkward postures. Estimates […]

vial needle 400w

FDA Approves Xeomin® as First-Line Treatment for Focal Eye Dystonia

The US Food & Drug Administration (FDA) has approved the use of the botulinum neurotoxin Xeomin® (incobotulinumtoxinA) as a first-line treatment of blepharospasm in adults, as announced in a press release from Merz. Blepharospasm is a focal dystonia that causes muscles around the eyes to contract involuntarily. Individuals with blepharospasm may experience excessive blinking, light […]